Assessment of therapeutic response of edaravone and riluzole combination therapy in amyotrophic lateral sclerosis patients
Conclusions: Combined with riluzole, edaravone slows disease progression and is safe, but the effect is short-term. Bulbar symptoms respond better to combination therapy. The serum creatinine is helpful in monitoring disease progression.
Source: Annals of Indian Academy of Neurology - Category: Neurology Authors: Swapnil Samadhiya Vijay Sardana Bharat Bhushan Dilip Maheshwari Ravi Goyal Pankaj Source Type: research
More News: Academies | ALS | Brain | India Health | Japan Health | Neurology | Respiratory Medicine | Study